Difference Between IBS-D and IBS-C Explained

IBS-D and IBS-C are not two different illnesses. They are two labels produced by a single rule, and the rule is narrower than almost anyone expects: it looks only at the shape of your stools, and only on days when your bowels are abnormal. Everything else about the diagnosis, including the pain criteria that make it IBS in the first place, is identical.

That one rule is why so many people end up arguing with their own label. You can have IBS-C and go three times in a day. You can have IBS-D and spend half of every month unable to go at all. You can be given one subtype at your first appointment and a different one two years later without anything new having gone wrong. This guide takes the rule apart, shows you the arithmetic on a real fortnight of logs, explains what is genuinely different underneath the two labels, and is honest about the large amount that is the same.

The short answer: stool form on abnormal days, nothing else

The difference between IBS-D and IBS-C is the proportion of your abnormal stools that are loose versus hard, measured on the Bristol Stool Form Scale. Nothing about pain, bloating, urgency, frequency or how bad your week was enters the calculation.

Rome IV, the criteria used by gastroenterologists worldwide, sets it out as a table (Lacy 2016, Schmulson 2017):

Bristol types 1 and 2 are separate hard lumps and a lumpy sausage. Types 6 and 7 are mushy fluffy pieces and entirely liquid. Types 3, 4 and 5 sit in between and are treated as normal for this purpose.

That last sentence is where most explanations of IBS subtypes quietly go wrong, and it is worth the next section on its own.

The rule change almost nobody explains: only abnormal days count

Under Rome III, the 25% threshold was calculated across every bowel movement you had, normal ones included. Under Rome IV it is calculated only across days with abnormal bowel movements. That single change moves large numbers of people from one label to another.

The Rome IV review states it plainly: bowel habits are now "based on stool forms only during days with abnormal bowel movements", in contrast to Rome III, where the 25% threshold used the total number of bowel movements regardless of whether they were normal (Schmulson 2017). The reason was practical. Under the old method, someone with mostly normal stools and occasional hard ones failed every threshold and fell into the unclassified bin, and in several population studies IBS-U ended up as the largest group. Excluding normal days shrinks that bin dramatically.

The change had a second, larger consequence worth knowing about. Rome IV also tightened the core IBS definition: pain became mandatory, "discomfort" was dropped because it does not translate consistently between languages, and the required frequency went up. In the Rome Foundation's worldwide survey of 73,076 adults, the proportion meeting IBS criteria was 4.1% by Rome IV against 10.1% by Rome III on the internet survey, and 1.5% against 3.5% on the household survey (Sperber 2021). So a lot of people who were called IBS under the older criteria no longer meet the stricter research definition, even though their symptoms are unchanged and their care is unaffected.

How to work out your own subtype: the arithmetic on two weeks of logs

The calculation takes about five minutes once you have the data. The data is the hard part, and it has to be recorded at the time, not reconstructed.

Step 1: log every bowel movement by Bristol type for two weeks. One number per movement. Nothing else is needed for the subtype calculation, although urgency, blood, night-time waking and whether you strained are worth recording for other reasons.

Step 2: delete every type 3, 4 and 5. Those are your normal movements. Under Rome IV they do not enter the sum at all.

Step 3: count what is left. Work out the share that are types 1 to 2 and the share that are types 6 to 7. Compare each against 25%.

Here is what that looks like on a real-shaped fortnight. Say you logged 26 movements over two weeks:

Thirteen movements are normal and drop out. Thirteen remain: 7 hard and 6 loose. That is 54% hard and 46% loose. Both are above 25%, so this pattern is IBS-M, not IBS-C and not IBS-D, even though the person logging it probably describes themselves as "mostly constipated with the odd bad day".

Now run the same 26 movements the Rome III way, across all stools: 7 of 26 hard is 27%, and 6 of 26 loose is 23%. Above 25% hard, below 25% loose, which is the definition of IBS-C. Same fortnight, same person, two different labels depending on which version of the rule you use. If you have ever been told two different subtypes by two different clinicians, this is one plausible explanation.

Why your memory gives the wrong answer

Recalled bowel habit and recorded bowel habit disagree far more often than people expect, and only the recorded version reflects what your gut is actually doing.

In a study of 54 people with IBS, researchers established the subtype twice: once from the patient's own account at the enrolment visit, and once from diary cards. They agreed in just 54% of cases, a level of agreement barely better than chance (kappa 0.28). The people whose two answers disagreed were not more anxious or psychologically distinct; they simply had more variable stool form. Most tellingly, colonic transit time correlated with stool form only when stool form had been written down on a diary card, not when it was recalled (Coletta 2010). The authors' conclusion was blunt: use diary cards.

Stool form is worth logging because it is a surprisingly good proxy for how fast things are moving. In the original validation study, 66 volunteers had whole-gut transit measured with radio-opaque markers and then had their transit deliberately altered. Transit time correlated with how often they went (r = 0.35) and with stool weight (r = -0.41), but correlated best with stool form (r = -0.54). When transit was changed, the change in stool form tracked it best of all (r = -0.65) (Lewis 1997). That is why the Bristol scale, and not "how many times did you go", sits at the centre of the subtype rule.

If you want the practical version of how to keep a log that will survive contact with real life, our guide to keeping a food diary for IBS covers what to write down and how to avoid the reconstruct-at-bedtime trap that ruins most diaries.

What is actually different underneath the two labels

Transit is genuinely different between the subtypes, and so is the amount of fluid sitting in different parts of the gut. This is the part of the IBS-D versus IBS-C difference that has objective evidence behind it.

A Nottingham study scanned 34 healthy volunteers, 30 people with IBS-D, 16 with IBS-C and 11 with IBS-M by MRI from fasting through to six hours after a meal (Lam 2017). Two findings stand out:

• Whole-gut transit was prolonged in IBS-C, at a median of 69 hours against 34 hours in both healthy volunteers and IBS-D. Note that IBS-D transit was not faster than normal in this study, it was simply normal.
• The transverse colon was bigger in IBS-C while fasting, at a median of 253 ml against 165 ml in healthy volunteers and 198 ml in the non-constipated IBS group. Bloating scores correlated with transverse colon volume, which offers a mechanism for why bloating is such a prominent complaint in IBS-C.
• The small bowel held less water in the non-constipated group. Fasting small bowel water content was 21 ml in the IBS non-constipated group against 44 ml in healthy volunteers.

The authors described this as a constricted small bowel in one group and a dilated transverse colon in the other, and argued it points to genuinely different underlying mechanisms. It is a small study and the IBS-C group in particular was only 16 people, so treat it as a strong signal rather than settled fact.

One thing that study also demonstrates is why the "IBS-D means your gut is racing" shorthand is too simple. Something in IBS-D makes stool loose and urgent without necessarily speeding up the whole journey, and in a meaningful minority of people that something has a name.

Pain is not the same in IBS-D and IBS-C

This is the finding most likely to surprise you: across two large surveys, abdominal pain was reported as more troublesome in IBS-C than in IBS-D, not less.

In a nationwide US survey, 1,158 adults with active IBS symptoms (245 IBS-D, 232 IBS-C, 681 IBS-M) completed standardised pain questionnaires. Pain scores were higher in IBS-C (percentile score 75.5) than in IBS-D (68.6). Pain in IBS-C was more bothersome, more frequent, and interfered more with daily activities than pain in IBS-D, and people with IBS-C and IBS-M reported more widespread pain than people with IBS-D (Shah 2020).

The Rome Foundation's global study reached a similar place from a much larger sample. Among 2,195 people with IBS drawn from 54,127 survey participants across 26 countries, pain in IBS-C was longer-lasting, more severe and more widespread, often radiating to the back and associated with greater use of painkillers. Pain in IBS-D was more tightly linked to changes in stool frequency and consistency, which fits the clinical picture of pain that comes and goes around bowel movements. Psychological distress was high in every subtype, at 69% to 78% (Hod 2026).

That same clinic series found a set of differences that are not about the bowel at all. People with IBS-D were more likely to report food intolerance (9.5%), to have had their gallbladder removed (17.8%) and to report faecal incontinence (36.2%). People with IBS-M had the highest depression questionnaire scores and the highest rates of joint pain, numbness in the limbs and chronic neck pain (Pereyra 2024). This is a single-country cross-sectional study, so read the numbers as descriptive rather than definitive, but the gallbladder finding in particular points somewhere useful.

What people actually live with, as opposed to what the label says

The percentage rule describes a fortnight of stool forms. It says nothing about which version is harder to live with, and community discussion makes clear that this depends almost entirely on circumstances rather than biology.

A long r/ibs thread asking whether anyone else prefers constipation to diarrhoea drew hundreds of replies that split almost evenly (r/ibs thread). The people who preferred diarrhoea described it as awful but finite: a bad half hour and then it is over, against days of unrelenting pressure. The people who preferred constipation described the opposite trade: pain they could endure at home against the constant fear of not reaching a toilet, of leaving customers mid-conversation, of a 20-minute commute being 20 minutes too long. Several people with predominantly one pattern said their view flipped the moment they experienced a bad spell of the other.

The same thread surfaces something the subtype rule cannot represent at all. A commenter described overflow diarrhoea: loose stool passing around a hard blockage, which produces the misery of both at once. Another described the sensation of desperately needing to go and being unable to, which is one of the most common complaints in the community and does not map onto a Bristol number in any clean way. A thread about mixed IBS opened with exactly that problem, and the most upvoted reply was simply "what about both at once?" (r/ibs thread).

People with IBS-C also describe feeling like a minority in a diarrhoea-dominated conversation. A post titled "ibs-c havers, what do you do????" opened by noting that most posts in the subreddit are about IBS-D, and one reply just said they wished there were a separate thread for it (r/ibs thread). That is a search-engine artefact as much as anything, and it is worth saying clearly: in the Rome Foundation's global sample, IBS-C was the single largest subtype at 712 of 2,195 people, level with IBS-M (Hod 2026).

Why your subtype keeps changing

Moving between subtypes is the norm, not a warning sign, and it is one of the best-documented facts about IBS that almost no subtype explainer mentions.

The definitive study followed 317 women with IBS for a year, reassessing bowel habit from two-week diary cards every three months. At baseline the group split roughly into thirds: 36% IBS-D, 34% IBS-C, 31% IBS-M. Over the year the size of each group barely changed, but the individuals inside them churned constantly. More than 75% of participants moved into a different subtype at least once. IBS-M was the least stable label, with half the group moving out of it within 12 weeks. Transitions were most common between IBS-M and IBS-C. Crucially, the full swing between IBS-D and IBS-C happened in only 29% of people over the whole year (Drossman 2005).

A later review found the same pattern in a clinical trial cohort: only one in four patients kept their baseline classification throughout, two in three moved between IBS-C and IBS-M, and over half switched between IBS-D and IBS-M. IBS-M was again the least stable group, and the review noted there is very little data on what actually drives these shifts (Yadav 2021).

So the honest framing is this. Drifting between IBS-C and IBS-M, or between IBS-D and IBS-M, is so common as to be unremarkable. Swinging all the way from one pole to the other is less common, and a sustained swing is worth mentioning at your next appointment, particularly if it arrived with anything new.

Things that plausibly push people across the line include:

• A new medication. Opioid painkillers are the clearest example, and Rome IV added opioid-induced constipation as its own category precisely because it is not IBS (Lacy 2016). In the r/ibs mixed-subtype thread, several people described a migraine preventive flipping them from mostly loose to mostly hard (r/ibs thread). If you notice a change in the weeks after starting anything new, that is information for your prescriber, not a reason to stop it yourself.
• A gut infection. Around 10.1% of people develop IBS within 12 months of an episode of infectious gastroenteritis, rising to 14.5% beyond 12 months, and the risk is about 4.2 times higher than in people who did not have the infection. The rate was highest after protozoal or parasitic infection (41.9%) and lower after bacterial infection (13.8%) (Klem 2017). Post-infection IBS tends to run with diarrhoea.
• Fibre and diet changes, in either direction.
• Starting or stopping laxatives or anti-diarrhoeals, which is the most mechanical reason of all.
• Hormonal cycling. If your pattern tracks your menstrual cycle rather than the calendar, our article on why IBS gets worse around a period covers what is known about that.

If your symptoms simply come and go without any of these explanations, that is also normal, and why IBS comes and goes covers the wider picture.

Where the subtype genuinely changes your care: testing

This is the most practical reason the label is worth getting right. Diarrhoea opens a specific set of investigations that constipation does not, and stubborn constipation opens a different set entirely.

If your pattern is diarrhoea-predominant, guidelines point towards a small number of specific tests:

• Coeliac serology. The ACG guideline suggests serologic testing to rule out coeliac disease in people with IBS and diarrhoea (Lacy 2021). A 2025 meta-analysis of 29 studies and 7,209 people with IBS found a pooled seroprevalence of 6% and biopsy-proven coeliac disease in 2%, with more than four times the odds of positive serology compared with controls. Notably, the odds were similar across IBS subtypes, so this is not a diarrhoea-only concern, but it is where the guideline emphasis sits (Shiha 2025).
• Faecal calprotectin. ACG suggests checking it in suspected IBS with diarrhoea to rule out inflammatory bowel disease (Lacy 2021). A meta-analysis found that a calprotectin of 40 µg/g or under, or a CRP of 0.5 or under, leaves roughly a 1% or lower probability of IBD (Menees 2015). Neither marker distinguishes IBS from healthy controls, which is the point: they are there to rule something else out, not to confirm IBS.
• Bile acid malabsorption. A meta-analysis of six studies and 908 people meeting criteria for IBS-D found bile acid malabsorption in a pooled 28.1% of them, using SeHCAT retention under 10%. Individual studies ranged from 16.9% to 35.3% (Slattery 2015). That is more than one in four people carrying an IBS-D label who have a specific, differently managed cause of their diarrhoea. Availability of the test varies a lot by country, and it is worth asking about explicitly, especially if your diarrhoea started after gallbladder surgery.
• Microscopic colitis, with an important caveat. A meta-analysis found that a third of people with microscopic colitis report symptoms compatible with IBS, but the odds of having microscopic colitis were no higher in people with IBS than in other people with diarrhoea. The authors concluded that the value of routine colonoscopy with biopsies to exclude it, in the absence of risk factors or alarm symptoms, remains uncertain (Kamp 2016). Age, duration and alarm features drive this decision, not the subtype label alone.

If your pattern is constipation-predominant and stubborn, the useful tests are often about the pelvic floor rather than the colon. In a study of 66 people with IBS, features of pelvic floor dyssynergia, where the muscles that should relax during defecation contract instead, were found in 41% of the IBS group against 5% of controls, and were present across all three subtypes (Mulak 2010). Rome IV explicitly extended the functional defecation disorder definition to include people with IBS-C, precisely because dyssynergia can coexist with IBS and is treated with biofeedback regardless (Schmulson 2017, Rao 2016). If you have been on laxative after laxative with no benefit, "has anyone assessed how my pelvic floor works when I try to go?" is a reasonable question to bring to an appointment.

For how to raise all this without derailing a ten-minute consultation, our guide on explaining IBS to your doctor covers how to lead with the pain, the stool pattern and the start date.

Where treatment diverges, and where it genuinely does not

The medicines aimed at bowel habit are subtype-specific. Almost everything else is not. Getting this the right way round stops a lot of wasted effort.

Subtype-specific. The ACG guideline recommends chloride channel activators and guanylate cyclase activators for IBS-C, and rifaximin for IBS-D (Lacy 2021). A network meta-analysis of 15 trials and 8,462 people found that linaclotide, lubiprostone, plecanatide and tenapanor were all superior to placebo in IBS-C, with broadly similar efficacy between them and diarrhoea as a common side effect of most (Black 2018). None of these are things to start, stop or swap on your own, and this article deliberately does not discuss doses. The point is simply that the drug conversation depends on which way your bowel habit runs.

Shared across subtypes. This list is longer than most people expect:

• Diet. The ACG recommends a limited trial of a low FODMAP diet to improve global IBS symptoms, without restricting that advice to a subtype (Lacy 2021). The original controlled feeding trial showed lower overall symptom scores on the low FODMAP arm across subtypes (Halmos 2014), and a network meta-analysis found it superior to habitual diet (Black 2022). A 2025 network meta-analysis of 28 trials and 2,338 people ranked a low FODMAP diet fourth of the interventions studied in more than one trial, behind a starch-reduced and sucrose-reduced diet that has so far only been tested in two trials (Cuffe 2025). The low FODMAP diet is a short, structured process with a planned reintroduction phase, ideally run with a dietitian, and it is not meant to be permanent.
• Fibre, with a caveat. A 2026 meta-analysis of 30 trials and 1,904 people found 52% responded to fibre against 44% on control (risk ratio 1.21, 95% CI 1.03 to 1.41), with the benefit driven by psyllium specifically (risk ratio 1.53, 95% CI 1.06 to 2.19). The authors noted that subgroup analysis by IBS subtype was not possible for most outcomes and called for future trials to report by subtype (Staudacher 2026). So the common belief that fibre is an IBS-C treatment and an IBS-D aggravator is not actually established either way by the trial evidence.
• Antispasmodics and gut-brain neuromodulators, which were analysed together across IBS in a network meta-analysis without subtype restriction (Black 2020).
• Psychological therapies. A network meta-analysis of psychological therapies found benefits across IBS rather than in one subtype (Black 2020), and ACG suggests gut-directed psychotherapy for global IBS symptoms (Lacy 2021).

The British Society of Gastroenterology guideline makes the broader point that IBS is now classed as a disorder of gut-brain interaction rather than a purely functional bowel problem, which is part of why so many of the effective treatments sit outside the bowel-habit drugs (Vasant 2021).

IBS-D and IBS-C at a glance

Sources for this table: Lacy 2016, Lam 2017, Shah 2020, Hod 2026, Pereyra 2024, Lacy 2021, Slattery 2015.

If you are IBS-M or IBS-U

IBS-M is not a consolation prize for people who did not fit elsewhere. It is a defined category with its own rule, it is one of the two largest subtypes, and by some measures it carries the heaviest burden.

In the Rome Foundation's global sample, IBS-M accounted for 712 of 2,195 people with IBS, exactly level with IBS-C, and IBS-U for 142 (Hod 2026). In the clinic series of 4,862 people, IBS-M was the largest group at 46.8%, had the highest mean symptom severity score, the highest depression questionnaire score and 80% reporting depressive symptoms, and the highest rates of symptoms outside the gut (Pereyra 2024).

It is also the least stable label, which cuts both ways. Half of one study's IBS-M group had moved out of it within 12 weeks (Drossman 2005). If you are IBS-M, expect your dominant pattern to shift, and expect a written log to be more useful to you than to anyone else, because it is the only thing that will let you or your clinician see which way the balance is tipping in any given month.

IBS-U, unclassified, means you meet the criteria for IBS but your bowel habits do not fit any of the three patterns (Lacy 2016). Because Rome IV excludes normal days from the calculation, this category is now much smaller than it was under Rome III (Schmulson 2017). If you have been given this label, it is worth asking whether it was assigned from a recalled history rather than a diary, since the two disagree about half the time (Coletta 2010).

A worked example: the same person, three appointments

Appointment one. Sam, 34, has had three years of cramping pain with bloating and hard, pellet-like stools. He tells his GP he goes "maybe twice a week, and it's always a battle". He is labelled IBS-C on that history alone and given general advice on fibre and fluid.

What was missing. No log existed, so the subtype came from recall. Recall and diary agree only about half the time (Coletta 2010). Sam had also not mentioned that about one week in four he has several days of urgent, loose stools he thinks of as "my body finally clearing out", because he did not think that counted.

Appointment two, five months later. Sam brings two weeks of Bristol-scale logs. Across 22 movements: 5 were type 1 or 2, 4 were type 6 or 7 and 13 were types 3 to 5. Discarding the normal ones leaves 9, of which 56% are hard and 44% are loose. Both above 25%, so his pattern over that fortnight is IBS-M. He also notes he had been taking a magnesium supplement in week two, which he had not thought of as a laxative. His GP notes that and asks him to repeat the log.

Appointment three. The repeat fortnight, without the magnesium, shows 4 of 11 abnormal stools loose (36%) and 7 hard (64%): still IBS-M, but the label is now based on recorded data twice rather than a sentence of recall once. Because loose stools are a consistent part of his pattern, his GP orders coeliac serology and a faecal calprotectin, which she would not have ordered for pure constipation (Lacy 2021). Both come back reassuring. The conversation then moves to a structured dietary trial with a dietitian, and to what to do about the pain, which was always the thing Sam actually wanted help with.

Nothing dramatic happened in that sequence. But two weeks of numbers changed which tests were ordered and closed off a plausible alternative diagnosis, which is more than most three-year symptom histories achieve.

This is the kind of record Clairop is built around: each bowel movement logged by Bristol type in a few taps, with urgency, blood and whether it woke you at night underneath, and a one-page summary you can hand over rather than a spreadsheet nobody will read. The method page explains how it compares symptoms across delay windows and why it holds back a result until it has seen enough days to mean anything.

Myths about IBS-D and IBS-C

Myth: "IBS-D means you have diarrhoea most of the time." It means more than a quarter of your abnormal stools were loose and fewer than a quarter were hard. If most of your days are normal, those days do not enter the calculation at all (Schmulson 2017).

Myth: "Changing subtype means you were misdiagnosed." More than three quarters of participants in a year-long study changed subtype at least once, while the size of each group stayed constant (Drossman 2005). Movement is the expected behaviour of the label.

Myth: "IBS-C is the milder one." In two large surveys, pain in IBS-C was more frequent, more bothersome and more widespread than in IBS-D (Shah 2020, Hod 2026). Severity depends on which symptom you measure.

Myth: "IBS-D means your gut is racing." In an MRI study, whole-gut transit in IBS-D was a median of 34 hours, identical to healthy volunteers. It was IBS-C that was clearly abnormal, at 69 hours (Lam 2017).

Myth: "Diarrhoea and constipation on the same day means something rare is wrong." Overflow around retained stool, and urgency with nothing passing, are both common experiences in the community, and the percentage rule is simply not designed to describe them. That does not make them mysterious; it makes them worth describing in words to your clinician rather than as a subtype.

Myth: "Fibre is for IBS-C and makes IBS-D worse." The meta-analysis that found psyllium helpful in IBS could not run subtype subgroups for most outcomes and explicitly called for trials that report by subtype (Staudacher 2026). The confident subtype split you see repeated online is ahead of the evidence in both directions.

Myth: "A subtype label tells you the cause." It describes stool form over a fortnight. More than a quarter of people meeting IBS-D criteria have bile acid malabsorption, which is a different mechanism with different management (Slattery 2015).

When to see a doctor

See a doctor rather than self-labelling if you have had bowel symptoms for weeks and have never had a formal assessment. IBS is now diagnosed positively, on the basis of typical symptoms and limited testing, rather than by excluding everything else one test at a time (Lacy 2021), so a consultation is not a hurdle to get past before anything can be done.

See a doctor promptly if you have any of these, whatever subtype you think you are:

• Blood in your stool, or black tarry stools
• Unintended weight loss
• A persistent change in bowel habit that began after the age of 50
• Symptoms that wake you from sleep
• A fever alongside gut symptoms
• Unexplained tiredness or breathlessness, which can point to anaemia
• A family history of bowel cancer, coeliac disease or inflammatory bowel disease
• A lump in the abdomen or rectum

Also worth an appointment sooner rather than later:

• Your subtype has swung all the way from one pole to the other and stayed there
• Your diarrhoea started after gallbladder surgery, or after an episode of food poisoning or travellers' diarrhoea
• Laxatives have stopped working, or you are escalating the dose to get the same effect
• You are avoiding an increasing number of foods to stay in control of your bowels
• Symptoms are affecting your work, sleep or mood

Red-flag symptoms need a doctor promptly, not a diary. Everything else in this article is background for a better conversation, not a substitute for one.

What to take to the appointment

Two things make the biggest difference, and neither requires an app.

A two-week Bristol log with dates. Not a summary, the raw numbers. If you can add urgency, straining, blood and night-time waking alongside, better. Note any laxative, anti-diarrhoeal, magnesium supplement, opioid painkiller or new medication you took during the fortnight, because all of them change the answer.

Three sentences about the pain. When it comes, where it is, and what it does around bowel movements. Rome IV made pain the defining feature of IBS and dropped the vaguer "discomfort" (Schmulson 2017), so pain is the part your clinician most needs described precisely. The subtype is arithmetic that anyone can do from your log in two minutes; the pain is the part only you can supply.

If you want to go further on isolating what sets your symptoms off once the subtype question is settled, how to find out what triggers your IBS covers the difference between a suspect and a proven trigger, and the rest of our IBS subtype guides go deeper on living with each pattern.